<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00325637</url>
  </required_header>
  <id_info>
    <org_study_id>CNL-BR3-01-02</org_study_id>
    <secondary_id>CHERISH Study</secondary_id>
    <nct_id>NCT00325637</nct_id>
  </id_info>
  <brief_title>Cilnidipine Effect on High Blood Pressure and Cerebral Perfusion in Ischemic Stroke Patients With Hypertension</brief_title>
  <official_title>A Multi-Center, Double Blind, Randomized and Non-Inferiority Clinical Study of Cilnidipine to Compare the Effects on Cerebral Blood Flow With Losartan in Patients With Ischemic Stroke Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of cilnidipine (a calcium channel blocker)
      and losartan (an angiotensin II receptor blocker) on cerebral blood flow (CBF) and blood
      pressure in hypertensive patients with a previous ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Multi-center, randomized, double-blind, active control, titrated dose,
      non-inferiority trial

      Population Studied: We will prospectively recruit 250 hypertensive patients who had ischemic
      stroke 2 or more weeks previously and were admitted at 7 centers in the Seoul metropolitan
      area in South Korea.

      Interventions: After a 2-week washout period, all patients will undergo baseline 99mTc-HMPAO
      single photon emission computed tomography (SPECT), blood pressure evaluation, NIHSS
      examination, and laboratory test prior to treatment. The patients will be randomized to
      receive either cilnidipine 10-20mg or losartan 50-100mg once daily for 4 weeks with a target
      systolic blood pressure of &lt; 140mmHg and diastolic blood pressure of &lt; 90mmHg. After 4-week
      treatment, all patients will receive follow-up SPECT and blood pressure evaluation. For the
      quantitative CBF analysis, SPECT will be performed with a single machine in one center.

      Outcome Measures: Primary outcome measure is the percentile change of global CBF on SPECT
      between pre- and post-treatments. Secondary outcome measures include the percentile change of
      regional CBF, the proportion of patients less than 8.6% decrease of global CBF, and the
      change of NIHSS score.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the changes of global cerebral blood flow</measure>
    <time_frame>from screnning to weeks 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentile change of regional CBF</measure>
    <time_frame>from screnning to weeks 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients less than 8.6% decrease of global CBF</measure>
    <time_frame>from screnning to weeks 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of NIHSS scores</measure>
    <time_frame>from screnning to weeks 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Hypertension</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>A,1,III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To compare the effect of cilnidipine (calcium channel blocker) and losartan (angiotension II receptor blocker) on CBF in patients with ischemic stroke</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilnidipine</intervention_name>
    <description>Cilnidipine 10~20mg, qd, po for 4 weeks.</description>
    <arm_group_label>A,1,III</arm_group_label>
    <other_name>Arms: Losartan, Cilnidipine</other_name>
    <other_name>Cinalong</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic stroke patients with hypertension

        Exclusion Criteria:

          -  Cardioembolic stroke patients

          -  Severe hypertensive patients

          -  Secondary hypertensive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong H Park, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Budang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeong H Rha, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ja S Koo, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eulji General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keun S Hong, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong S Lee, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Boramae Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong W Kang, Assistant Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Budang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://clinic.boryung.co.kr/</url>
  </link>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2006</study_first_submitted>
  <study_first_submitted_qc>May 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2006</study_first_posted>
  <last_update_submitted>December 11, 2008</last_update_submitted>
  <last_update_submitted_qc>December 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Choi, Jeongeun/Director</name_title>
    <organization>Boryung Pharmaceutical Co., Ltd</organization>
  </responsible_party>
  <keyword>CHERISH</keyword>
  <keyword>Ischemic Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Cilnidipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

